Year: 2026
Type: editorial
Abstract: This patent discloses a series of substituted indazole compounds as novel inhibitors of KRAS, with potential utility as anticancer therapeutics. The invention describes the chemical structures of these substituted indazoles, their pharmaceutical compositions, and methods of use for treating KRAS-driven malignancies. The disclosed compounds are designed to modulate oncogenic KRAS signaling and may offer a new therapeutic strategy for cancers associated with KRAS mutations.
Source: ACS Medicinal Chemistry Letters
Authors: Jian Rong, Steven H. Liang
Language: English
Subfield: Organic Chemistry
Field: Chemistry
Domain: Physical Sciences
Open Access status: bronze
OpenAlex ID: W7133519871